Somewhat Positive News Coverage Somewhat Unlikely to Affect Aralez Pharmaceuticals (ARLZ) Share Price

News articles about Aralez Pharmaceuticals (NASDAQ:ARLZ) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.346262404971 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Aralez Pharmaceuticals (NASDAQ ARLZ) opened at $1.68 on Thursday. The company has a debt-to-equity ratio of 4.64, a current ratio of 1.00 and a quick ratio of 0.92. Aralez Pharmaceuticals has a twelve month low of $0.95 and a twelve month high of $4.79. The company has a market cap of $106.35, a PE ratio of -0.99 and a beta of 1.37.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The business had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. During the same quarter in the prior year, the business posted ($0.32) EPS. Aralez Pharmaceuticals’s revenue for the quarter was up 78.7% compared to the same quarter last year. sell-side analysts expect that Aralez Pharmaceuticals will post -1.54 earnings per share for the current year.

In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch acquired 50,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $1.47 per share, with a total value of $73,500.00. Following the acquisition, the director now directly owns 271,609 shares of the company’s stock, valued at $399,265.23. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aralez-pharmaceuticals-arlz-share-price/1799820.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.